Barclays Upgrades Chemours (NYSE:CC) to Hold

Chemours (NYSE:CC) was upgraded by analysts at Barclays to a “hold” rating in a report issued on Monday, Zacks reports.

Several other research firms also recently issued reports on CC. BMO Capital Markets reduced their price objective on Chemours from $26.00 to $18.00 and set an “outperform” rating on the stock in a report on Thursday, August 13th. Weiss Ratings cut Chemours from a “sell (d)” rating to a “sell (d-)” rating in a research note on Thursday, August 6th. UBS Group lowered their target price on Chemours from $18.00 to $16.00 and set a “neutral” rating for the company in a research note on Monday, October 5th. Royal Bank Of Canada downgraded Chemours from an “outperform” rating to a “sector perform” rating and set a $14.00 target price for the company. in a research report on Tuesday. Finally, The Goldman Sachs Group reaffirmed a “neutral” rating and set a $16.00 price target on shares of Chemours in a research note on Friday, October 9th. Three analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $18.09.

Chemours Price Performance

Shares of CC stock opened at $12.81 on Monday. Chemours has a 1 year low of $10.44 and a 1 year high of $28.67. The firm’s 50 day moving average is $14.79 and its 200-day moving average is $18.97. The firm has a market capitalization of $1.93 billion, a price-to-earnings ratio of -6.71 and a beta of 1.41. The company has a current ratio of 1.66, a quick ratio of 0.88 and a debt-to-equity ratio of 18.98.

Chemours (NYSE:CC) last released its quarterly earnings results on Tuesday, August 4th. The specialty chemicals company reported $0.42 EPS for the quarter, missing the consensus estimate of $0.49 by ($0.07). The company had revenue of $1.59 billion for the quarter, compared to the consensus estimate of $1.65 billion. Chemours had a negative net margin of 5.00% and a positive return on equity of 60.64%. Chemours’s revenue for the quarter was down 1.5% compared to the same quarter last year. During the same period last year, the company earned ($2.54) earnings per share. Sell-side analysts forecast that Chemours will post 0.84 EPS for the current fiscal year.

Insider Transactions at Chemours

In other Chemours news, insider Calderon Gerardo Familiar purchased 1,935 shares of the company’s stock in a transaction that occurred on Wednesday, August 12th. The stock was acquired at an average cost of $15.53 per share, with a total value of $30,050.55. Following the completion of the purchase, the insider directly owned 58,547 shares in the company, valued at approximately $909,234.91. This represents a 3.42% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Shane Hostetter purchased 3,350 shares of the company’s stock in a transaction that occurred on Thursday, August 6th. The shares were acquired at an average cost of $14.94 per share, with a total value of $50,049.00. Following the completion of the purchase, the chief financial officer owned 102,698 shares of the company’s stock, valued at $1,534,308.12. The trade was a 3.37% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders acquired a total of 8,663 shares of company stock worth $130,601 in the last quarter. 0.85% of the stock is owned by company insiders.

Institutional Trading of Chemours

A number of institutional investors have recently bought and sold shares of CC. BlackRock Inc. bought a new stake in Chemours in the second quarter valued at approximately $477,769,000. Wolf Hill Capital Management LP bought a new position in shares of Chemours during the second quarter worth $59,698,056. Bank of New York Mellon Corp bought a new position in shares of Chemours during the second quarter worth $33,353,000. Legal & General Group Plc bought a new position in shares of Chemours during the second quarter worth $28,400,000. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of Chemours during the second quarter worth $18,119,000. Institutional investors and hedge funds own 76.26% of the company’s stock.

Chemours News Summary

Here are the key news stories impacting Chemours this week:

• Positive Sentiment: BMO Capital reaffirmed its Buy rating, indicating that some analysts still see recovery potential in Chemours despite the recent weakness. BMO Capital reaffirms Buy rating
• Neutral Sentiment: Barclays initiated coverage at Equal Weight, while Mizuho maintained a Neutral rating but reduced its price target to $15 from $18. The new target still implies potential upside from recent trading levels, but the cut signals more cautious expectations. Mizuho downgrades Chemours
• Negative Sentiment: RBC Capital downgraded Chemours to Sector Perform from Outperform and cut its price target to $14 from $22, citing persistent TiO₂ weakness, soft chemical demand and potential headwinds in the Thermal & Specialized Solutions segment through year-end. RBC downgrades Chemours
• Negative Sentiment: Several law firms announced or promoted a securities-fraud class action filed against Chemours and certain officers. The case covers investors who purchased shares from February 20 through August 4, 2026, and alleges investors were harmed by disclosures concerning Opteon refrigerant aftermarket demand. The lead-plaintiff deadline is December 7, 2026. Although the allegations have not been proven, the litigation creates legal, financial and reputational risks. Chemours securities-fraud class action

Chemours Company Profile

The Chemours Company (NYSE: CC) is a global chemical company that develops, manufactures and distributes specialty chemical products used in a range of industrial and consumer applications. Its portfolio serves markets including coatings, plastics, automotive, refrigeration and air conditioning, electronics, telecommunications, energy, healthcare and general manufacturing.

Chemours operates through three primary business segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials.